Hypertension:青年时期血清尿酸变化轨迹与中年心血管疾病事件

2021-06-19 MedSci原创 MedSci原创

青年期血清尿酸升高轨迹与中年期CVD事件相关,这种关联可以用暴露期间的血压水平进行解释。

血清尿酸水平已被证明与中年或老年人发生血管疾病 (CVD) 事件的风险相关。然而,青年时期的血清尿酸盐变化轨迹及其与CVD事件之间的关联尚未得到充分研究。

近日,心血管权威杂志Hypertension上发表了一篇研究文章,研究人员收集了3563名CARDIA(年轻成人冠状动脉风险发展)研究参与者(平均年龄为25.1±3.6 [基线时为18-30岁,第0年,1985-1986 年];46.3%为黑人;56.1%为女性)的血清尿酸测量值 。

研究人员采用SAS PROC TRAJ确定了性别特异性的血清尿酸变化轨迹。研究人员估计了从20次评估到2017年期间发生的CVD事件(冠心病、心力衰竭和卒中)风险比。研究人员按性别确定了3个血清尿酸变化轨迹,包括低稳定 (n=1251)、中稳定 (n=1761) 和高增长 (n=551)。

血清尿酸的变化轨迹

在中位10.6年的随访期间,共发生了157起CVD事件。与低稳定轨迹组相比,高增长组的参与者患CVD的风险高出2.89倍(95%CI为1.88-4.43)。在调整了青年时期的血压水平后,这种关联有所减弱。

总之,青年期血清尿酸升高轨迹与中年期CVD事件相关,这种关联可以用暴露期间的血压水平进行解释

原始出处:

Nagisa Morikawa.et al.Serum Urate Trajectory in Young Adulthood and Incident Cardiovascular Disease Events by Middle Age: CARDIA Study.Hypertension.2021.https://doi.org/10.1161/HYPERTENSIONAHA.121.17555

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700621, encodeId=9c7c1e0062147, content=<a href='/topic/show?id=a75e3809094' target=_blank style='color:#2F92EE;'>#变化轨迹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38090, encryptionId=a75e3809094, topicName=变化轨迹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b330204743, createdName=FukaiBao, createdTime=Thu Mar 31 03:50:06 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728984, encodeId=1e8d1e2898429, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 03 10:50:06 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039260, encodeId=4c8720392601e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 22 18:50:06 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976039, encodeId=ce269e6039b4, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=870f5149029, createdName=137*****860<手机用户>4572, createdTime=Wed Jun 23 08:41:19 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466378, encodeId=3fab14663e84c, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498899, encodeId=650f14988999d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501537, encodeId=fa04150153ea1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974876, encodeId=803e9e48767b, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq3roWQ6pYFo2weDrJEjaD7MpMqORRs0nurfWdVjEwhsdciaeQJcmLz0xVEMpY1csyB93Pt0p4oiayA/132, createdBy=015e2506437, createdName=kelvinyang, createdTime=Sat Jun 19 14:53:23 CST 2021, time=2021-06-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1700621, encodeId=9c7c1e0062147, content=<a href='/topic/show?id=a75e3809094' target=_blank style='color:#2F92EE;'>#变化轨迹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38090, encryptionId=a75e3809094, topicName=变化轨迹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b330204743, createdName=FukaiBao, createdTime=Thu Mar 31 03:50:06 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728984, encodeId=1e8d1e2898429, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 03 10:50:06 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039260, encodeId=4c8720392601e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 22 18:50:06 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976039, encodeId=ce269e6039b4, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=870f5149029, createdName=137*****860<手机用户>4572, createdTime=Wed Jun 23 08:41:19 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466378, encodeId=3fab14663e84c, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498899, encodeId=650f14988999d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501537, encodeId=fa04150153ea1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974876, encodeId=803e9e48767b, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq3roWQ6pYFo2weDrJEjaD7MpMqORRs0nurfWdVjEwhsdciaeQJcmLz0xVEMpY1csyB93Pt0p4oiayA/132, createdBy=015e2506437, createdName=kelvinyang, createdTime=Sat Jun 19 14:53:23 CST 2021, time=2021-06-19, status=1, ipAttribution=)]
    2021-12-03 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1700621, encodeId=9c7c1e0062147, content=<a href='/topic/show?id=a75e3809094' target=_blank style='color:#2F92EE;'>#变化轨迹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38090, encryptionId=a75e3809094, topicName=变化轨迹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b330204743, createdName=FukaiBao, createdTime=Thu Mar 31 03:50:06 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728984, encodeId=1e8d1e2898429, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 03 10:50:06 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039260, encodeId=4c8720392601e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 22 18:50:06 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976039, encodeId=ce269e6039b4, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=870f5149029, createdName=137*****860<手机用户>4572, createdTime=Wed Jun 23 08:41:19 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466378, encodeId=3fab14663e84c, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498899, encodeId=650f14988999d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501537, encodeId=fa04150153ea1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974876, encodeId=803e9e48767b, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq3roWQ6pYFo2weDrJEjaD7MpMqORRs0nurfWdVjEwhsdciaeQJcmLz0xVEMpY1csyB93Pt0p4oiayA/132, createdBy=015e2506437, createdName=kelvinyang, createdTime=Sat Jun 19 14:53:23 CST 2021, time=2021-06-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1700621, encodeId=9c7c1e0062147, content=<a href='/topic/show?id=a75e3809094' target=_blank style='color:#2F92EE;'>#变化轨迹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38090, encryptionId=a75e3809094, topicName=变化轨迹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b330204743, createdName=FukaiBao, createdTime=Thu Mar 31 03:50:06 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728984, encodeId=1e8d1e2898429, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 03 10:50:06 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039260, encodeId=4c8720392601e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 22 18:50:06 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976039, encodeId=ce269e6039b4, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=870f5149029, createdName=137*****860<手机用户>4572, createdTime=Wed Jun 23 08:41:19 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466378, encodeId=3fab14663e84c, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498899, encodeId=650f14988999d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501537, encodeId=fa04150153ea1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974876, encodeId=803e9e48767b, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq3roWQ6pYFo2weDrJEjaD7MpMqORRs0nurfWdVjEwhsdciaeQJcmLz0xVEMpY1csyB93Pt0p4oiayA/132, createdBy=015e2506437, createdName=kelvinyang, createdTime=Sat Jun 19 14:53:23 CST 2021, time=2021-06-19, status=1, ipAttribution=)]
    2021-06-23 137*****860<手机用户>4572

    不错的文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1700621, encodeId=9c7c1e0062147, content=<a href='/topic/show?id=a75e3809094' target=_blank style='color:#2F92EE;'>#变化轨迹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38090, encryptionId=a75e3809094, topicName=变化轨迹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b330204743, createdName=FukaiBao, createdTime=Thu Mar 31 03:50:06 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728984, encodeId=1e8d1e2898429, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 03 10:50:06 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039260, encodeId=4c8720392601e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 22 18:50:06 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976039, encodeId=ce269e6039b4, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=870f5149029, createdName=137*****860<手机用户>4572, createdTime=Wed Jun 23 08:41:19 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466378, encodeId=3fab14663e84c, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498899, encodeId=650f14988999d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501537, encodeId=fa04150153ea1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974876, encodeId=803e9e48767b, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq3roWQ6pYFo2weDrJEjaD7MpMqORRs0nurfWdVjEwhsdciaeQJcmLz0xVEMpY1csyB93Pt0p4oiayA/132, createdBy=015e2506437, createdName=kelvinyang, createdTime=Sat Jun 19 14:53:23 CST 2021, time=2021-06-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1700621, encodeId=9c7c1e0062147, content=<a href='/topic/show?id=a75e3809094' target=_blank style='color:#2F92EE;'>#变化轨迹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38090, encryptionId=a75e3809094, topicName=变化轨迹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b330204743, createdName=FukaiBao, createdTime=Thu Mar 31 03:50:06 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728984, encodeId=1e8d1e2898429, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 03 10:50:06 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039260, encodeId=4c8720392601e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 22 18:50:06 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976039, encodeId=ce269e6039b4, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=870f5149029, createdName=137*****860<手机用户>4572, createdTime=Wed Jun 23 08:41:19 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466378, encodeId=3fab14663e84c, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498899, encodeId=650f14988999d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501537, encodeId=fa04150153ea1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974876, encodeId=803e9e48767b, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq3roWQ6pYFo2weDrJEjaD7MpMqORRs0nurfWdVjEwhsdciaeQJcmLz0xVEMpY1csyB93Pt0p4oiayA/132, createdBy=015e2506437, createdName=kelvinyang, createdTime=Sat Jun 19 14:53:23 CST 2021, time=2021-06-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1700621, encodeId=9c7c1e0062147, content=<a href='/topic/show?id=a75e3809094' target=_blank style='color:#2F92EE;'>#变化轨迹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38090, encryptionId=a75e3809094, topicName=变化轨迹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b330204743, createdName=FukaiBao, createdTime=Thu Mar 31 03:50:06 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728984, encodeId=1e8d1e2898429, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 03 10:50:06 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039260, encodeId=4c8720392601e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 22 18:50:06 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976039, encodeId=ce269e6039b4, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=870f5149029, createdName=137*****860<手机用户>4572, createdTime=Wed Jun 23 08:41:19 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466378, encodeId=3fab14663e84c, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498899, encodeId=650f14988999d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501537, encodeId=fa04150153ea1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974876, encodeId=803e9e48767b, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq3roWQ6pYFo2weDrJEjaD7MpMqORRs0nurfWdVjEwhsdciaeQJcmLz0xVEMpY1csyB93Pt0p4oiayA/132, createdBy=015e2506437, createdName=kelvinyang, createdTime=Sat Jun 19 14:53:23 CST 2021, time=2021-06-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1700621, encodeId=9c7c1e0062147, content=<a href='/topic/show?id=a75e3809094' target=_blank style='color:#2F92EE;'>#变化轨迹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38090, encryptionId=a75e3809094, topicName=变化轨迹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b330204743, createdName=FukaiBao, createdTime=Thu Mar 31 03:50:06 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728984, encodeId=1e8d1e2898429, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Dec 03 10:50:06 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039260, encodeId=4c8720392601e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Mar 22 18:50:06 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976039, encodeId=ce269e6039b4, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=870f5149029, createdName=137*****860<手机用户>4572, createdTime=Wed Jun 23 08:41:19 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466378, encodeId=3fab14663e84c, content=<a href='/topic/show?id=6eda8939206' target=_blank style='color:#2F92EE;'>#血清尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89392, encryptionId=6eda8939206, topicName=血清尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99066802687, createdName=feifers, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498899, encodeId=650f14988999d, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501537, encodeId=fa04150153ea1, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Jun 21 03:50:06 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974876, encodeId=803e9e48767b, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq3roWQ6pYFo2weDrJEjaD7MpMqORRs0nurfWdVjEwhsdciaeQJcmLz0xVEMpY1csyB93Pt0p4oiayA/132, createdBy=015e2506437, createdName=kelvinyang, createdTime=Sat Jun 19 14:53:23 CST 2021, time=2021-06-19, status=1, ipAttribution=)]
    2021-06-19 kelvinyang

    好文

    0

相关资讯

Lancet:糖尿病患者一定具有高心血管疾病风险吗?

糖尿病患者不一定具有高心血管疾病风险,要根据患者的具体情况进行个体化的评估

NEJM:阿司匹林剂量在心血管疾病中的疗效比较

在这项涉及心血管疾病患者的实用试验中,每天服用81 mg阿司匹林治疗的患者和每天服用325 mg阿司匹林治疗的患者间心血管事件或大出血无显著差异。

ATVB:咀嚼能力与心血管疾病风险生物标志物的关系

与咀嚼能力较差相关的饮食改变以及由此导致的腹部肥胖可能导致IL-6水平升高和NTproBNP水平降低。

Psychological Medicine:抑郁症与心血管疾病有关

抑郁症与代谢改变有关,这可能是抑郁症与心血管疾病之间的联系机制

JACC:脂肪组织分泌的神经酰胺可直接影响心血管疾病患者的死亡率!

脂肪组织来源的神经酰胺是肥胖个体血管氧化还原状态的可调节的调节剂,直接影响晚期动脉粥样硬化患者的心源性死亡率

Nat Commun:深度学习模型预测肺癌筛查中低剂量计算机断层扫描的心血管疾病风险

心血管疾病(CVD)影响了近一半的美国成年人,并造成超过30%的死亡人数。